Brief: ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix
09/05/2022 06:08
May 9 (Reuters) - OBSEVA SA OBSN.S :
* OBSEVA PRESENTS CLINICAL DATA ON ORAL GNRH ANTAGONIST
LINZAGOLIX
FOR THE TREATMENT OF UTERINE FIBROIDS AT THE 2022 ACOG ANNUAL
CLINICAL AND SCIENTIFIC MEETING
* ANNOUNCED PRESENTATION OF CLINICAL DATA FROM PRIMROSE (1
AND 2)
PHASE 3 STUDIES OF LINZAGOLIX FOR TREATMENT OF HEAVY MENSTRUAL
BLEEDING ASSOCIATED WITH UTERINE FIBROIDS AT AMERICAN COLLEGE OF
OBSTETRICIANS AND GYNECOLOGISTS (ACOG) ANNUAL CLINICAL AND
SCIENTIFIC MEETING (ACSM)
Source text for Eikon: ID:nGNE5r4z8k
Further company coverage: OBSN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary